Phathom Pharmaceuticals Begins Phase 2 EoE Trial
I'm PortAI, I can summarize articles.
Phathom Pharmaceuticals (PHAT) has announced the start of its Phase 2 pHalcon EoE-201 clinical trial for VOQUEZNA® (vonoprazan) tablets, targeting eosinophilic esophagitis in adults. The trial will enroll 80 participants, with results expected in 2027. Analysts rate PHAT stock as a Buy with a $22.00 price target, though Spark's AI Analyst gives it a Neutral outlook due to financial instability and reliance on external financing. Phathom focuses on gastrointestinal disease treatments, with a current market cap of $976.7M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments